Health Care

Council for Citizens Against Government Waste Releases 2017 Congressional Ratings

(Washington, D.C.) – The Council for Citizens Against Government Waste (CCAGW) today released its 2017 Congressional Ratings, highlighting the voting records of all 535 voting members of Congress during the first session of the 115th Congress.  The report, which CCAGW has issued since 1989, identifies members whose voting records helped protect taxpayer dollars, as well as those who consistently voted against their interests.

Any Willing Pharmacy – Not as Good as it Sounds

On November 28, 2017, the Centers for Medicare and Medicaid Services (CMS) published a proposed rule that would revise Medicare Part D, the prescription drug program.  The proposal dredges up the “any willing pharmacy” issue that would require any Part D plan sponsor, such as an insurer or a pharmacy benefit manager (PBM), to allow any pharmacy to participate in their network.  While this policy has a benign name, if it is adopted, it will drive up costs for all Medicare beneficiaries, not lower them.

The VA Scandal Refuses to End

America’s armed forces represent the best of our country.  These men and women put their lives on the line to protect us.  That is why they deserve the highest quality medical care when they return home.  However, countless investigations and internal reports over the past decade have exposed a systemic cancer of mismanagement, neglect, and failure at the Department of Veterans Affairs (VA).

The BBA, Medicare Part D, and a Cautionary Tale

When President Trump signed the Bipartisan Budget Act (BBA) for fiscal years 2018 and 2019 on February 9, 2018, Citizens Against Government Waste (CAGW) objected because of its prolific and irresponsible spending, calling the $300 billion (14 percent) increase over current levels “outrageous and unnecessary, as well as a complete abdication of fiscal discipline and accountability.”

New FDA Report on BPA: It is Still Safe

On February 23, 2018, the Food and Drug Administration (FDA) released a statement by Deputy Commissioner for Foods and Veterinary Medicine Stephen Ostroff, M.D., regarding a draft report issued by the National Toxicology Program (NTP) on the compound bisphenol A, more commonly referred to as BPA.

Trump Administration Reverses Obama-era Rule on Health Insurance

On Tuesday, February 20, the Department of Health and Human Services (HHS) released a long-awaited proposed rule that would change an Obama administration rule that curtailed short-term, limited-duration health insurance (STLDI) plans.  The HHS press release stated, “In dir

Drug Prices - The Council of Economic Advisers and Trump Administration Weigh In

Last Friday, on February 9, 2018, the White House Council of Economic Advisers released a 30-page report on, “Reforming Biopharmaceutical Pricing at Home and Abroad.”  There is enough in the report to please or give heartburn to all the players in the pharmaceutical distribution chain but, there are many significant ideas that policy makers should and will consider.  President Trump’s administration has already done so for its 2019 budget proposal, which will be discussed briefly in this blog.

FDA Tobacco Products Scientific Advisory Committee Weighs in on IQOS

On January 24 and 25, 2018, the Food and Drug Administration’s (FDA) nine-member Tobacco Products Scientific Advisory Committee (TPSAC) reviewed the Modified Risk Tobacco Product Applications (MRTPA) on an innovative tobacco product, named the IQOS, which is designed to reduce the harm associated with tobacco use.  CAGW discussed the MRTPA and the advisory committee meeting in a

FDA Advisory Committee to Discuss New Tobacco Harm Reduction Product

The Family Smoking and Prevention and Tobacco Control Act (TCA) became law in June 2009 and gave the Food and Drug Administration (FDA) authority to regulate the manufacture, distribution, and marketing of all tobacco products.  Included in the law is Section 918, which called for a report to Congress on how best to regulate, promote, and encoura

Taxpayers and Patients Win First Round on 340B Drug Discount Rule

Citizens Against Government Waste (CAGW) discussed in its November 7, 2017 WasteWatcher blog, a Centers for Medicare and Medicaid Services (CMS) final rule for Medicare Part B that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program.

Pages

Sign Up for Email Updates!Click Here!

CAGW Names Sen. Kamala Harris August 2018 Porker of the Month

Sen. Harris is CAGW's Porker of the Month for for proposing an expensive and impractical taxpayer-funded rent subsidy.